Research applications · Immuno-oncology
Tissue & data for immuno-oncology research
Study immune biomarkers in their tumor context with clinically characterized tissue microarrays and FFPE cohorts. Select tissue by immune infiltration, treatment history and available response data, with additional assays and pathology support as needed.
Tissue selection for immune biomarker research
Connect the tumor microenvironment to clinical context
Immune context
Tumor center & invasive margin
Explore selected arrays with cores from distinct tissue regions, alongside collection-specific immune infiltration assessments and PD-L1 (22C3) scores.
Treatment response
Clinically characterized cohorts
Define study groups using available treatment regimens, response and follow-up. Selected NSCLC tissue microarrays include second-line immunotherapy follow-up.
Changes with treatment
Pre- & post-treatment tissue
Compare tissue collected before and after treatment. Choose donor-matched collections where available; other collections contain separate patient groups.
Immune assessments, tissue regions and clinical fields vary by array and donor. Pre/post treatment does not necessarily mean donor-matched tissue.
Selected arrays
Tissue microarrays for immuno-oncology studies
Explore arrays selected for immune infiltration, immunotherapy follow-up or paired tissue comparison. Each TMA has its own tissue composition and associated data.
HIGH IMMUNE INFILTRATES · ARRAY 1 · TA4312
Multi tumor array comprising cores with high immune infiltrates from NSCLC, Bladder(UC), Ovarian, Gastric & RCC. TMA1 (TA4312) of a set of 2 TMAs, histopath data
- Approx. cores
- 120
- Approx. donors
- 60
- Core diameter
- 1mm
HIGH IMMUNE INFILTRATES · ARRAY 2 · TA4313
Multi tumor array comprising cores with high immune infiltrates from Pancreatic, Melanoma, Breast, HCC & CRC. TMA2 (TA4313) of a set of 2 TMAs, histopath data
- Approx. cores
- 120
- Approx. donors
- 60
- Core diameter
- 1mm
NSCLC · IMMUNOTHERAPY FOLLOW-UP · TA4301
NSCLC with 2nd line IO follow up & optional RNAseq, GeoMx (protein & RNA panels), DAB IHC data (TA4301)
- Approx. cores
- 38
- Approx. donors
- 38
- Core diameter
- 1mm
NSCLC · DONOR-MATCHED PRE/POST · TA3111
NSCLC donor matched pre & post treatment samples with follow up data (TA3111)
- Approx. cores
- 28
- Approx. donors
- 14
- Core diameter
- 1mm
Counts are approximate. Product details and datasheets describe the available case-level information and assay suitability.
Browse all TMAs
Tissue, immune profiles & follow-up
Study immune patterns alongside treatment response
Clinically annotated specimens connect tissue findings to the donor record. Available data can include treatment regimen and line, clinician-recorded response, survival and last follow-up.
Existing molecular results and optional RNA-seq, GeoMx or IHC datasets are collection-specific. New profiling can be discussed separately for your selected tissue.
Study planning
Match the immune question to tissue and data
Start with the biological comparison, then identify the tissue regions, collection timing and available clinical records needed to interpret it.
Checkpoint expression and immune composition
Use selected tissue with IHC and pathology scoring to investigate checkpoint expression and immune-cell markers. Specify the relevant tumor or immune-cell compartment and scoring approach. A marker-positive tissue group and a group enriched for immune infiltration answer different questions.
Spatial relationships
Tumor-center and invasive-margin cores can support comparisons between defined regions. When the question concerns where immune populations sit within tissue, discuss whole sections, image analysis or spatial profiling. Agree on the regions to evaluate and the level of cellular detail required before selecting an assay.
Treatment and response context
Distinguish treatment-naïve tissue linked to later immunotherapy outcomes from tissue collected during or after treatment. For longitudinal comparisons, confirm donor matching and collection timing. Request the available regimen, line of therapy, recorded response and follow-up fields, alongside the assay outputs required. Associations in these cohorts do not by themselves establish a predictive biomarker of treatment benefit.
Planning expression-frequency comparisons? See biomarker prevalence studies. For tumor-target and T-cell context together, explore bispecific research.
Assays & pathology support
Add assays around your study question
Select protein, RNA or multiplex measurements to complement your tissue cohort and available donor data.
Protein expression
IHC assay services
Characterize immune checkpoints and immune-cell markers in your selected tissue, with pathology review and study-specific scoring.
Explore IHC servicesSpatial RNA expression
RNAscope RNA-ISH
Localize target RNA in FFPE tissue, with pre-qualified samples, assay controls and pathologist scoring.
Explore RNAscopeMultiplex protein imaging
Multiplex immunofluorescence
Distinguish immune cell phenotypes and examine their spatial relationships with tumor cells using multiplex immunofluorescence.
Research & references
Research using TriStar tissue and data
Author affiliations
Enable Medicine
TriStar Technology Group
Author affiliations
Istituto Oncologico del Mediterraneo
Seoul National University College of Medicine
+1 more organizations
- TriStar Technology Group
Organizations are identified from author affiliations, patent records and report credits. Their inclusion does not imply a partnership with or endorsement of TriStar.
Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
Plan your study
Discuss your immuno-oncology study
Tell us your cancer indication, immune biomarkers, treatment context and required follow-up. We’ll review suitable TMAs, FFPE cohorts and any assays or pathology support you would like to add.